TECHNOLOGICAL APPROACHES TO DEVELOPMENT OF WHOLE-VIRION INACTIVATED VACCINE FROM RECOMBINANT STRAIN AGAINST A/H5N1 INFLUENZA IN THE REPUBLIC OF KAZAKHSTAN


Cite item

Full Text

Abstract

Aim. Development of technological stages of preparation of experimental influenza whole-virion inactivated
adsorbed vaccine based on recombinant influenza virus strains NIBRG-14 and А/Аstana/RG/6:2/2009.
Materials and methods. 2 recombinant vaccines influenza strains were used in the study - NIBRG-14 and
А/Аstana/RG/6:2/2009. Purification of native virus-containing allantoic fluid was performed by ion-exchange
chromatography. The virus was inactivated by formaldehyde. Merthiolate at concentration of 0.1 mg/ml was
added to the vaccine as a preserving substance. Aluminium hydroxide was used as an adjuvant. Harmlessness
and immunogenicity (HI) of the constructed preparation are determining. Results. Virus-containing materials
from recombinant strains with biological activity of 8.5 - 9.0 lg EID50/cm3 and hemagglutination activity
of 1:256 - 1:1024 in chicken embryos were obtained. Optimal inactivation regimen of non-purified
suspensions by formaldehyde was established and combined scheme of purification and concentration of
influenza virus was selected that provide harmlessness and immunogenicity of experimental samples of inactivated
vaccines against highly pathogenic influenza A/H5N1 in experiments in mice. Conclusion. The
data obtained on quality parameters of intermediate products and final vaccine give evidence on their compliance
with normative parameters for whole-virion influenza purified vaccine.

References

  1. Ершебулов З.Д., Абдураимов Е.О., Рыскельдинова Ш.Ж. и др. Определение оптимальных параметров культивирования рекомбинантного штамма А/Астана/RG/5:3/2009 вируса гриппа. Биотехнология. Теория и практика. 2010, 4: 75-79.
  2. Соминина А.А., Милькинт К.К., Амосова И.В. и др. Выделение вирусов гриппа в клеточных культурах и куриных эмбрионах и их идентификация. Метод. реком. М., 2006.
  3. Atmar R.L., Keitel W.A., Patel S.M. et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin. Infect. Dis. 2006, 43 (9): 1135-1142.
  4. Czermak P., Grzenia D.L., Wolf A. et al. Purification of the densonucleosis virus by tangential flow ultrafiltration and by ion exchange membranes. Desalination. 2008, 224: 23-27.
  5. Goldstrein M.A. Effect of formalin, 3-propiolactone, merthiolate, and ultraviolet light upon influenza virus infectivity, chicken cell agglutination, hemagglutination, and antigenicity. Appl. Microbiol.. 1970, 19 (2): 290-294.
  6. Goyal S.M., Hanssen H., Gerba C.P. Simple method for the concentration of influenza virus from allantoic fluid on microporous filters. Appl. Environ. Microbiol. 1980, 39 (3): 500-504.
  7. Hehme N., Engelmann H., Kuenzel W. et al. Immunogenicity of a monovalent, aluminumadjuvanted influenza whole virus vaccine for pandemic use. Virus Res. 2004, 103 (1-2): 163-171.
  8. Horimoto T., Takada A., Fujii K. et al. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine. 2006, 24: 3369-3676.
  9. John J. Treanor et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 2006, 354: 1343-1351.
  10. Kalbfuss B., Wolff M., Morenweiser R. et al. Purification of cell culture-derived human influenza A virus by size-exclusion and anion-exchange chromatography. Biotechnol. Bioengin. 2007, 96 (5): 932-944.
  11. Kang S. Intranasal immunization with inactivated iInfluenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens. J. Virol. 2004, 78 (18): 9624-9632.
  12. Lin J., Zhang J., Dong X. Safety and immunogenicity of an inactivated adjuvanted wholevirion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet. 2006, 368 (9540): 991-997.
  13. Neumann G., Watanabe T., Ito H. et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. USA. 1999, 96: 9345-9350.
  14. Ninomiya A., Imai M., Tashiro M. et al. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine. 2007, 25: 3554-3560.
  15. Peterka M., Strancar A., Banjac M. et al. Method for influenza virus purification. EP20060116979 07/11/2006, C12N7/02.
  16. Takada A. Avirulent avian influenza virus as a vaccine strain against a potential human pandemic. J. Virol. 1999, 73 (10): 8303-8307.
  17. Waite D.C., Jacobson E.W., Ennis F.A. et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine. 2001, 19 (28-29): 3957-3967.
  18. WHO Expert Committee on Biological Standardization: Fifty-fourth report. Geneva, World Health Organization, 2003 (WHO Technical Report Series, No. 927).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Kydyrbaev Z.K., Mamadaliev S.M., Asanzhanova N.N., Tabynov K.K., Ryskel'dinova S.Z., Chervyakova O.V., Sandybaev N.T., Khayrullin B.M., Kiselev O.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies